Piper Jaffray analyst Joseph Catanzaro attributes the 20% decline in Immunomedics shares to the circulation of a report that highlights the issuance of a Form 483 following a pre-approval manufacturing inspection this past August. Immunomedics management emphasized that they continue to interact with the FDA on almost a daily basis and feel they are "in a very good place," said Catanzaro, who views the pullback as overdone and would be a buyer on weakness. He keeps an Overweight rating on Immunomedics, citing his confidence that sacituzumab will be approved by its January PDUFA date.